D-4F
Apolipoprotein A-I mimetic peptide D-4F
18 Amino Acids · MW: ~2300 Da
Amino Acids
18
Molecular Weight
~2300 Da
Half-life
Longer than L-form in vivo; still short relative to proteins
Research Score
4.6
Studies
92
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is D-4F?
D-4F is the D-amino-acid version of the apoA-I mimetic 4F peptide and is one of the best-known cholesterol-focused research peptides. It has been studied for lowering atherogenic inflammation, improving HDL function, and reducing vascular oxidative stress.
Key Benefits & Mechanisms
improves cholesterol efflux
enhances HDL anti-inflammatory activity
reduces oxidative stress
may reduce atherosclerotic lesions
Research Summary
D-4F has been widely used in preclinical lipid research because D-amino-acid peptides are more resistant to proteolysis. Studies show effects on HDL remodeling, oxidized lipid binding, and atherosclerosis-related inflammation.
Related Peptides
Carperitide
Recombinant human atrial natriuretic peptide (α-hANP)
Recombinant human atrial natriuretic peptide used mainly in acute heart failure and perioperative volume overload. It promotes natriuresis, vasodilation, and suppression of RAAS signaling to lower preload and afterload.
CardiovascularNesiritide
Recombinant human B-type natriuretic peptide (BNP-32)
Synthetic BNP used to counteract fluid overload and elevated cardiac filling pressures. It increases cyclic GMP, causing venous and arterial vasodilation plus natriuresis.
CardiovascularUlaritide
Synthetic human urodilatin
Urodilatin is a renal natriuretic peptide derived from the proANP precursor and studied as an IV heart-failure therapy. It produces strong natriuresis and vasodilation with a relatively rapid onset.
CardiovascularCenderitide
CD-NP chimeric natriuretic peptide
Cenderitide is a designer natriuretic peptide combining features of CNP and dendroaspis natriuretic peptide. It was engineered to provide balanced natriuretic and vasodilatory activity with potential renal-sparing effects.
Cardiovascular